Health Tips


Vaxneuvance™ (Pneumococcal 15‑valent Conjugate Vaccine)

Pneumonia is the second leading cause of death in Hong Kong, with a mortality rate of 30-47% for infection with serotype 3 pneumococcus. Pneumococcus can cause diseases, including common ones like otitis media and pneumonia, and invasive pneumococcal diseases, leading to severe or fatal illnesses. Serotype 3 is also considered the top killer among invasive pneumococcal diseases. Between 2016 and 2020, nearly 70% of invasive pneumococcal diseases in infants and young children in Hong Kong were caused by serotype 3.
Vaxneuvance™ (Pneumococcal 15‑valent Conjugate Vaccine)
  • Precision targeting of the current epidemic of serotype 3 pneumococcus in Hong Kong
  • Prevention of 15 types of pneumococcus serotypes(1、3、4、5、6A、6B、7F、9V、14、18C、19A、19F、22F、23F、33F)
  • Compared to existing vaccines, there is up to 73% increase in immune response, specifically targeting serotype 3 in infants and young children
  • *If an adult has already received the 13-valent pneumococcal conjugate vaccine or the 23-valent pneumococcal polysaccharide vaccine, they can receive the 15-valent pneumococcal conjugate vaccine one year after the previous vaccination. It is also recommended to consult with your family doctor before receiving any vaccination
Suggested for vaccination
  • 6 weeks infant or above
  • elder
  • High-risk individuals (such as those who have suffered from invasive pneumococcal disease, diabetes, chronic heart disease, lung disease, liver disease or immunocompromised persons, etc.)

Pneumococcal 15‑valent Conjugate VaccineVax-vac
  • Unique technology induces a stronger immune response, especially for serotype 3, which is 60% more effective than existing vaccines

  • People over 18 years old only need 1 injection (intramuscular injection)